Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX

NCT03660059 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT03660059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03660059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2018
Completion date
November 2, 2021
Enrollment
385 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)